Arvinas

Arvinas

World Rank (Jan-05-2024)
5,263
Market Cap (Jan-05-2024)
2.279 Billion USD
World Rank (Jul-30-2023)
7,862
Market Cap (Jul-30-2023)
1.197 Billion USD
World Rank (Jan-07-2022)
4,198
Market Cap (Jan-07-2022)
3.646 Billion USD
World Rank (Jan-01-2021)
3,492
Market Cap (Jan-01-2021)
4.017 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
ARVN
Market Cap (Mar-08-2026)
0.87
Employee Count
280
Employee Count as of Date
As on 2021
Headquarters City/State
Connecticut
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
131 Million USD
Annual Operating Income in USD
-263 Million USD
Annual Net Income in USD
-282 Million USD
Annual Results for Period Ending
Dec-2022 ending year
Total Assets in USD
1,268 Million USD
Total Liabilities in USD
703 Million USD
Total Equity in USD
564 Million USD
Balance Sheet for Period Ending
Dec-2022 ending year
Business Sector
Healthcare
Biotechnology
Biopharmaceutical
Company Website
ARVINAS
Yahoo
Yahoo @ Nasdaq
Company Profile

Arvinas is a Clinical Stage Biopharmaceutical company. It is focused on developing new therapeutics for cancers and other difficult to treat diseases and on high value targets in cancer including the androgen and estrogen receptors associated with prostate and breast cancers, respectively. The headquarters is in USA.

Annual Results Summary

ARVINAS - Yearly Revenue and Net Income - in Million USD:

Year - EndingRevenueOperating IncomeNet Income
Dec-2022131-263 (Loss)-282 (Loss)
Dec-202146-195 (Loss)-191 (Loss)
Dec-202021-124 (Loss)-119 (Loss)
Dec-201942-51 (Loss)-70 (Loss)
Dec-201814-43 (Loss)-239 (Loss)
Balance Sheet Summary

Total Assets as on Dec-2022 was 1,268 Million USD.

Total Liabilities as on Dec-2022 was 703 Million USD.

Total Equity as on Dec-2022 was 564 Million USD

Founded Year
2013
IPO Year
2018
Stock Exchange
Nasdaq
Company SubCategory
Top Healthcare Companies in USA
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share